Mobile Health Delivered Lifestyle Intervention Program in Patients With NASH
- Conditions
- Non-alcoholic Steatohepatitis
- Interventions
- Behavioral: Noom Healthy Weight
- Registration Number
- NCT04872777
- Lead Sponsor
- Milton S. Hershey Medical Center
- Brief Summary
There is a clear unmet clinical need for effective lifestyle intervention in patients with nonalcoholic steatohepatitis (NASH). Patients have self-identified multiple barriers to effective lifestyle intervention can be removed with a mobile health (mHealth) platform.
This study will be a proof of concept study to evaluate weight loss efficacy of Noom Healthy Weight (HW), a mHealth lifestyle intervention, in patients with NASH.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 40
- Adults age >18 years
- NASH defined as:
- Liver biopsy with evidence of steatohepatitis (NAS >=4) or;
- Imaging study (e.g., ultrasound, CT, MRI) with hepatic steatosis and one of the following:
- Fibroscan kPa >8.2 or;
- FAST > 0.35 or;
- FIB-4 >= 1.45 or;
- Possession of a smartphone
- Active or recent (<90 days) participation in lifestyle intervention program, including weight-loss program
- Active weight-loss supplement use
- Cirrhosis
- Inability to provide informed consent
- Institutionalized/prisoner
- Other chronic liver disease (e.g., viral hepatitis)
- Recent Noom use (<180 days)
- Secondary cause of hepatic steatosis, including significant alcohol consumption (men >30g/d, women >20g/d)
- Severe medical comorbidities/psychiatric illness at the discretion of the study PI
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description Noom Healthy Weight Noom Healthy Weight Following study group assignment, the following procedures will be completed for the Noom HW mHealth lifestyle intervention: 1. Noom application set-up and troubleshooting on smartphone (license provided) 2. Digital scale provision (subjects may keep the scale) 3. Capture of available clinical information over preceding 28-days.
- Primary Outcome Measures
Name Time Method Weight 16 weeks Change in self-measured body weight
- Secondary Outcome Measures
Name Time Method hemoglobin A1c 16 weeks Change hemoglobin A1c (%)
histology 16 weeks Change in transient elastography or liver histology
liver enzymes 16 weeks Change in liver enzymes units per liter (alanine transaminase (ALT), aspartate transaminase (AST), alkaline phosphatase (ALP))
NAFLD Fibrosis Score 16 weeks change in NAFLD Fibrosis Score
Noom healthy weight engagement 16 weeks Feasibility will be assessed according to user engagement. Engaged users are defined as those who complete at least one meaningful in-application action per week (e.g., weight log, food log, exercise log, article read).
Glucose 16 weeks Change in blood glucose mg/dL
Cholesterol level 16 weeks Change in cholesterol mg/dL
Ferritin 16 weeks Change in Ferritin ng/mL
IgA level 16 weeks Change in IgA level mg/dL
Trial Locations
- Locations (1)
Penn State Hershey Medical Center
🇺🇸Marietta, Pennsylvania, United States